Genetic Testing Market Key Players Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts

Genetic Testing Market Size and Forecast 2025-2033

The market for genetic testing is projected to reach approximately USD 49.72 billion by 2033, growing from USD 23.55 billion in 2025. This expansion is expected to occur at a compound annual growth rate (CAGR) of 9.79% between 2025 and 2033. Key applications driving this growth include oncology, rare disease diagnostics, and prenatal testing, which highlight the essential role of genetic testing in providing improved healthcare solutions globally.

Genetic testing refers to a variety of medical tests that analyze an individual's DNA to identify genetic disorders, predispositions, and potential risks for certain diseases. It examines specific genes, chromosomes, or proteins to provide insight into genetic conditions, inherited traits, and sometimes even responses to medications. This testing can inform healthcare decisions, guide treatments, and aid in preventive measures.

In recent years, genetic testing has gained significant popularity worldwide, driven by advancements in technology and increasing public awareness. Many people seek genetic tests for various reasons, including curiosity about ancestry, reproductive planning, and personal health management. The rise of direct-to-consumer testing services has made it more accessible, allowing individuals to learn about their genetic makeup from the comfort of their homes.

Additionally, the growing emphasis on personalized medicine has further fueled interest in genetic testing. Healthcare providers can tailor treatments based on an individual's genetic profile, enhancing effectiveness and minimizing risks. As our understanding of genetics continues to evolve, genetic testing is becoming an integral part of modern medicine and lifestyle choices, reshaping how we approach health care globally.

Top 5 Company in the Genetic Testing Market by 2033

1. Abbott Laboratories

Headquarters: United States of America

Founded: 1888

Abbott Laboratories is a prominent company in the medical devices and healthcare sectors, specializing in the discovery, development, manufacturing, and sale of a diverse range of products. The company's offerings primarily include gastroenterology and women's health products, along with solutions for cardiovascular and metabolic health, pain management, and central nervous system disorders. Additionally, Abbott produces respiratory drugs and vaccines, biosimilars, core laboratory systems, and transfusion medicine technologies. Their product line also encompasses point-of-care systems, rapid diagnostic lateral flow tests, informatics and automation solutions, nutritional products, as well as devices related to rhythm management, electrophysiology, and heart failure. The company addresses a wide array of vascular and structural heart needs, as well as neuromodulation therapies. Abbott distributes its products through various channels, including wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers. This extensive distribution network spans multiple regions, including North America, Latin America, the Middle East, Europe, Asia-Pacific, and Africa.

2. Illumina Inc.

Founded: 1998

Headquarters: San Diego, CA

Illumina Inc. is an American biotechnology company and one of the leading companies in the development of integrated systems for the analysis of genetic variation and biological functions. Its customers include pharmaceutical companies, genomic research centers, clinical research organizations, and other biotechnology companies. Over the years, Illumina has taken several strategic initiatives to enhance its product portfolio and increase its presence across geographies. It formed a partnership with aploX in December 2023 to manufacture sequencing instruments locally in China, enabling better access to advanced sequencing in the region.

3. Roche Ltd.

Founded: 1896

Headquarters: Basel Switzerland

Roche is a leading Swiss-based multinational healthcare company with operations around the world in two key businesses: pharmaceuticals and diagnostics. Since its establishment, Roche has been committed to developing innovative medicines and diagnostic tools that make a significant difference to patients' lives. So far, it has produced specialized treatments in many medical fields, including infectious diseases, ophthalmology, immunology, and oncology. An outstanding achievement by Roche is that 30 of its medicines are on the World Health Organization's list of essential medicines, solving many health problems worldwide.

4. Thermo Fisher Scientific

Founded: 2006

Headquarters: United States of America

Thermo Fisher Scientific Inc is a leading supplier of a broad range of analytical instruments, life sciences solutions, and specialty diagnostics. The company's product portfolio comprises laboratory essentials, advanced instruments for clinical applications, chromatography and mass spectrometry systems, and molecular biology instruments. Thermo Fisher customers include pharmaceutical and biotechnology companies, research institutions, universities, and government agencies. The company markets its products under several brands: Thermo Scientific, Applied Biosystems, and Fisher Scientific, among others, through direct sales, customer service, e-commerce sites, and third-party distributors.

5. Danaher Corporation

Headquarters: United States of America

Founded: 1984

Danaher Corporation is a major science and technology company that develops healthcare and life sciences solutions using biotechnology and diagnostic tools. The company designs and delivers a wide range of test instruments and medical diagnostic products. Its product portfolio includes life sciences research instruments, professional microscopes, mass spectrometry reagents, genomic consumables, filtration systems, flow cytometers, lab automation instruments, centrifugation instruments, and particle counting and characterization instruments. Danaher sells its products to pharmaceutical and biotechnology companies, healthcare facilities, and research institutions through independent distributors in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. Manufacturing facilities are located in Europe, Australia, Asia, and the Americas.

Product Launches

BioRad Laboratories Inc.

Jun 2024, Bio-Rad Laboratories, Inc. has launched the ddSEQTM Single-Cell 3' RNA-Seq Kit and Omnition v1.1 analysis software, designed for single-cell transcriptome research. Compatible with Bio-Rad's ddSEQ Cell Isolator, the kit provides high-quality single-cell RNA-Seq libraries through an efficient workflow, facilitating gene expression analyses. The Omnition v1.1 software supports data QC, analysis, and reporting, offering insights valuable for fields like oncology, immunology, neurology, and stem cell biology.

Myriad Genetics, Inc.

Sept. 2025, Myriad Genetics, a leader in molecular diagnostic testing and precision medicine, has partnered with SOPHiA GENETICS, an AI technology company focused on transforming precision medicine. Together, they will develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This collaboration will harness Myriad's advanced laboratory capabilities in the U.S. to support global testing for clinical trials, while leveraging SOPHiA GENETICS' extensive decentralized network of over 800 connected institutions across more than 70 countries to facilitate worldwide test deployment.

SWOT Analysis of Company

Diasorin

Strength - Diasorin S.p.A.: Strong Molecular Diagnostics Expertise and Integrated Genetic Testing Capabilities

Diasorin's greatest strength in the genetic testing market lies in its advanced molecular diagnostics expertise and well-established technological platform portfolio. The company's strong focus on nucleic acid amplification, molecular assay development, and automation allows it to deliver accurate, reliable, and scalable genetic testing solutions. Its flagship LIAISON(R) MDX and related molecular systems enable high-throughput, fully automated genetic analysis suitable for both clinical and research applications. Diasorin's extensive R&D capabilities and collaborations with healthcare institutions support the continuous expansion of its genetic testing menu, including infectious diseases, oncology, and hereditary disorders. With a global presence and reputation for diagnostic precision, the company's integration of innovation, quality, and regulatory compliance gives it a competitive edge. By combining technological expertise with strong global distribution, Diasorin effectively positions itself as a trusted provider of next-generation genetic testing systems that support personalized medicine.

Quest Diagnostics Incorporated

Strength - Quest Diagnostics Incorporated: Extensive Network and Leadership in Clinical Genomics

Quest Diagnostics Incorporated's greatest strength in the genetic testing market lies in its comprehensive diagnostic infrastructure and leadership in clinical genomics. With one of the largest laboratory networks in the world, Quest offers broad accessibility to advanced genetic testing services, including hereditary disease screening, oncology genomics, and pharmacogenomics. Its extensive database of clinical results and genomic insights enables unparalleled analytical accuracy and benchmarking in personalized healthcare. Quest's investment in digital health integration and partnerships with biopharmaceutical companies enhance its innovation pipeline and support precision medicine development. The company's robust logistics network and automated lab systems ensure timely, high-quality genetic test results for clinicians and patients globally. Combined with a strong reputation for reliability, data integrity, and affordability, Quest Diagnostics' scale and scientific leadership make it a key player in expanding access to genetic testing and driving innovation in personalized healthcare solutions.

Recent Development in Genetic Testing Market

Revvity Inc.

Jan 2025, Revvity, Inc. announced a partnership with Element Biosciences, Inc. to commercialize an in vitro diagnostic (IVD) workflow for neonatal sequencing. This collaboration builds on Revvity's recent automated next-generation sequencing (NGS) solution and supports Element's pursuit of regulatory approval for its AVITI(TM) sequencing system. Customers will also gain immediate access to a research use only (RUO) version of the workflow.

QIAGEN N.V.

April 2025, QIAGEN N.V. has announced a series of updates related to its products and partnerships aimed at enhancing its portfolio for cancer genomic profiling. Key updates include the introduction of new QIAseq panels for comprehensive genomic profiling (CGP), a new QIAcuity digital PCR (dPCR) kit, and assays for quality control in cell and gene therapy. Additionally, QIAGEN's Digital Insights (QDI) bioinformatics division is releasing a free, limited version of the Human Somatic Mutation Database (HSMD).

Sustainability Goal

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings (Labcorp) is committed to integrating sustainability into its mission of improving health and advancing life. Its sustainability goals focus on environmental responsibility, social equity, and ethical governance. Labcorp aims to achieve net-zero greenhouse gas emissions by 2050, emphasizing energy-efficient laboratory operations, renewable energy adoption, and waste reduction. The company promotes sustainable sourcing and minimizes single-use plastics in testing processes. Socially, Labcorp is dedicated to advancing health equity, expanding access to diagnostics, and supporting underrepresented communities through patient assistance and education programs. The company also prioritizes employee safety, diversity, and well-being, recognizing its workforce as a key driver of innovation. Transparent governance and responsible data management reinforce its accountability. By combining innovation, ethics, and sustainability, Labcorp seeks to create long-term value-delivering high-quality healthcare services while contributing to a more sustainable and equitable global health system.

Eurofins Scientific SE

Eurofins Scientific SE's sustainability goal is rooted in its mission to contribute to a safer, healthier, and more sustainable world through science and innovation. The company's strategy focuses on reducing its environmental footprint by achieving carbon neutrality across operations by 2050, improving energy efficiency, and transitioning to renewable energy sources. Eurofins actively develops and applies analytical testing methods that support sustainable agriculture, food safety, environmental protection, and clean energy initiatives. The company emphasizes green laboratory practices, including waste minimization, efficient chemical use, and eco-friendly logistics. Socially, Eurofins promotes employee well-being, ethical sourcing, and equitable access to testing solutions that protect public health. Its strong commitment to transparency and adherence to ESG (Environmental, Social, and Governance) standards ensures responsible business conduct. Through continuous innovation and responsible operations, Eurofins aims to empower industries and communities to thrive in a safer, cleaner, and more sustainable global environment.

Market Segmentation

Genetic Testing Market

• Historical Trends
• Forecast Analysis

Market Share Analysis - Genetic Testing Market

Abbott Laboratories

Overview

• Company History and Mission
• Business Model and Operations
• Workforce

Key Persons

• Executive Leadership
• Operational Management
• Division Leaders
• Board Composition

Recent Development & Strategies

• Mergers & Acquisitions
• Partnerships
• Investments

Sustainability Analysis

• Renewable Energy Adoption
• Energy-Efficient Infrastructure
• Use of Sustainable Packaging Materials
• Water Usage and Conservation Strategies
• Waste Management and Circular Economy Initiatives

Product Analysis

• Product Profile
• Quality Standards
• Product Pipeline
• Product Benchmarking

Strategic Assessment: SWOT Analysis

• Strengths
• Weaknesses
• Opportunities
• Threats

Revenue Analysis

The above information will be available for all the following companies:

1. Abbott Laboratories

2. Danaher Corporation

3. Illumina Inc.

4. BioRad Laboratories Inc.

5. F Hoffmann-La Roche AG

6. Diasorin

7. Revvity Inc.

8. Thermo Fisher Scientific Inc.

9. QIAGEN N.V.

10. Myriad Genetics, Inc.

11. Quest Diagnostics Incorporated

12. Laboratory Corporation of America Holdings

13. Eurofins Scientific SE

14. Agilent Technologies, Inc.

15. BGI Genomics Co., Ltd.

16. Invitae Corporation

17. Natera, Inc.

18. PerkinElmer, Inc.

19. Biocartis N.V.

20. Guardant Health, Inc.